Skip to main content
Altuviiio logo

Patient Experiences - Brooklynn


“I was excited to learn about ALTUVIIIO.”        
 

An accident at a talent show

The first time I remember having a bleed was in middle school. I was performing with my friends in a talent show, and they dropped me on my back. I quickly developed a back bleed. At that time, I was taking factor therapy on demand, and it wasn't a good match for me.        
 

Seeing the need for protection 

In March of 2023, our local hemophilia chapter had an event for ALTUVIIIO. I was excited to learn about it and consider it as a treatment option for me. I talked to my healthcare team about my concerns with my prior treatment and my treatment goals, and that conversation provided a lot of reassurance and helped me feel confident in my decision to switch to ALTUVIIIO. My healthcare team explained everything about ALTUVIIIO really clearly, including the potential benefits and side effects. We thoroughly discussed the transition from on-demand to prophylaxis treatment before I made the switch.          
 

Making the switch 

Taking it prophylactically helped me with bleed reduction. ALTUVIIIO makes me feel confident in my level of protection. I worry less while doing outside activities.

 

Moving forward with prophylaxis  

ALTUVIIIO turned out to be the right fit for me. I switched from infusing on-demand to prophylaxis treatment in 2023, and I haven’t looked back. Now I go once a year to see my healthcare team, but if I need anything, I can just call. My nurse, Stephanie, is the best. I encourage my doctors and nurses to talk openly with their other hemophilia A patients, just like they did with me, and see if ALTUVIIIO could be a good fit for them.    

This testimonial reflects one patient’s experience and has not been clinically evaluated. It is not intended to imply typical outcomes or substitute for clinical evidence. Brooklynn is a promotional speaker compensated by Sanofi. 

Discover More Patient Experiences

Indication

ALTUVIIIO® is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment and control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. Discontinue use of ALTUVIIIO if hypersensitivity reaction occurs and manage symptoms as appropriate.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of ALTUVIIIO. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

Indication

Important Safety Information

© 2026 Sanofi. All rights reserved. All trademarks mentioned are the property of the Sanofi group.